Drug Delivery Systems FDA Approval Life Science RNA 
Drug Discovery World
AUGUST 9, 2023
The life sciences sector has seen significant M&A activity over the last few weeks. The new acquisition gives Biogen rights to Reata’s portfolio of products for neurological diseases, including the FDA-approved Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s ataxia (FA) in the United States.
XTalks
AUGUST 30, 2022
Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. However, according to Dr. Vornov, the use of intrathecal delivery in drug development is unexplored for small molecules and peptides besides what has already been proved.
Expert insights. Personalized for you.
52 
Let's personalize your content